{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=teplizumab",
    "query": {
      "intervention": "teplizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=teplizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T07:25:03.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00239720",
      "title": "PsA Treatment With hOKT3γ1 (Ala-Ala)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "hOKT3gamma1(Ala-Ala)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2006-03-16",
      "completion_date": "2008-06-25",
      "has_results": true,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Chicago, Illinois",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239720"
    },
    {
      "nct_id": "NCT00870818",
      "title": "Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Blood samples for safety",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Patient reported outcome questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Analysis of T-cell subsets",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "37 Years",
        "sex": "ALL",
        "summary": "10 Years to 37 Years"
      },
      "enrollment_count": 219,
      "start_date": "2009-02",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870818"
    },
    {
      "nct_id": "NCT00129259",
      "title": "Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Anti-CD3 mAb",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diabetes Standard of Care Treatment",
          "type": "OTHER"
        },
        {
          "name": "Iron supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "8 Years to 30 Years"
      },
      "enrollment_count": 83,
      "start_date": "2005-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-22",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129259"
    },
    {
      "nct_id": "NCT00954915",
      "title": "Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "teplizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-12",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Portland, Oregon",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00954915"
    },
    {
      "nct_id": "NCT02067923",
      "title": "AbATE Follow-Up Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "37 Years",
        "sex": "ALL",
        "summary": "10 Years to 37 Years"
      },
      "enrollment_count": 44,
      "start_date": "2014-02",
      "completion_date": "2016-11-17",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02067923"
    },
    {
      "nct_id": "NCT05757713",
      "title": "Teplizumab in Pediatric Stage 2 Type 1 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "teplizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "0 Years to 7 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-07-25",
      "completion_date": "2026-08-27",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757713"
    },
    {
      "nct_id": "NCT03751007",
      "title": "A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetes type1"
      ],
      "interventions": [
        {
          "name": "AG019 - Low Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Teplizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo-AG019",
          "type": "DRUG"
        },
        {
          "name": "Placebo-Teplizumab",
          "type": "DRUG"
        },
        {
          "name": "AG019 - High Dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Precigen Actobio T1D, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 45,
      "start_date": "2018-10-24",
      "completion_date": "2021-10-13",
      "has_results": true,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03751007"
    },
    {
      "nct_id": "NCT00385697",
      "title": "The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Teplizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "8 Years to 35 Years"
      },
      "enrollment_count": 554,
      "start_date": "2006-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00385697"
    },
    {
      "nct_id": "NCT01030861",
      "title": "Teplizumab for Prevention of Type 1 Diabetes In Relatives \"At-Risk\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoantibody Positive",
        "Non-diabetic Relatives at Risk for Type 1 Diabetes",
        "High Risk",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Teplizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 76,
      "start_date": "2010-08",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 13 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01030861"
    },
    {
      "nct_id": "NCT07360080",
      "title": "Long-Term Outcomes of Teplizumab in Routine Clinical Care",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Teplizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2026-03-19",
      "completion_date": "2035-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-04T07:25:03.775Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • New York, New York • Syosset, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Syosset",
          "state": "New York"
        },
        {
          "city": "Sandy City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360080"
    }
  ]
}